The RESCUE trial was a phase 2, randomized, double-blind study evaluating the effects of ziltivekimab, a fully human monoclonal antibody targeting the IL-6 ligand, in patients at high atherosclerotic risk—specifically those with moderate to severe CKD and elevated hsCRP ≥ 2 mg/L. This evidence concerns the gene IL6 and chronic kidney disease.